UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2006
MannKind Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
000-50865
(Commission File Number)
|
|
13-3607736
(IRS Employer
Identification No.) |
| |
|
|
28903 North Avenue Paine
Valencia, California
(Address of principal executive offices)
|
|
91355
(Zip Code) |
Registrant’s telephone number, including area code: (661) 775-5300
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
| |
|
|
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
1.
Item 7.01 Regulation FD Disclosure.
We have held discussions with a number of pharmaceutical companies concerning a potential strategic
business collaboration for our Technosphere Insulin System. We have narrowed the list of potential
collaborative partners but are not disclosing the number or identity of any potential partner. To
date, we have neither concluded these discussions nor reached an agreement concerning such a
collaboration. There can be no assurance that any strategic collaboration will be available to us
on a timely basis or on acceptable terms, if at all.
2.